A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.
about
Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapyImmune Activation: Contribution to AIDS-Associated Non-Hodgkin LymphomaCigarette smoking and variations in systemic immune and inflammation markersBody mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance.Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Application of multiplex arrays for cytokine and chemokine profiling of bileAssociation between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialThe serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patientsAssociations of Coffee Drinking with Systemic Immune and Inflammatory Markers.Occupational Exposure to Benzene and Non-Hodgkin Lymphoma in a Population-Based Cohort: The Shanghai Women's Health StudyUsing Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies.Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United StatesThe clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study.CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.Discovery and application of immune biomarkers for hematological malignancies.Gastrointestinal follicular lymphoma: Current knowledge and future challenges.Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.The Relation of Obesity-Related Hormonal and Cytokine Levels With Multiple Myeloma and Non-Hodgkin Lymphoma.Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohortsPre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
P2860
Q33687930-9C42E97D-2A3C-4079-8862-0EE5557BE8C0Q33877471-54FA35B1-A83E-4AAF-ADA3-25DA8AFC433DQ33884484-19DC6880-7EE7-4E16-A85E-703013C633D3Q33887336-1C10BFA8-9050-4877-9A69-788EFBCD3C04Q34354166-20BFE559-695F-4017-B4C5-6246FE5E3D70Q34642100-7768C563-DB35-482B-9FC9-360D4922A5B3Q35056309-D4744F91-BCDA-4FCC-AF45-16BA89356053Q35242261-19088558-1B55-44C1-862C-8D81203E22F9Q35562771-5D542AD3-6235-4215-903F-F8AF8279EFA8Q35624432-3651EFDE-3A46-42F2-84CD-A7052D94FABFQ35815652-D8D4A4A7-4E38-4EFB-8E27-A781F485228AQ36112009-49EB2B58-454F-452C-897C-C2C6AF7C9B71Q36403297-C23CDD34-AC3C-447B-A085-4D969E9E1C83Q36471585-BE7C2643-5711-47DC-8F69-B7AA44A4EC88Q36924290-5D24AA43-8051-454E-906F-295AF166363AQ36983335-135678DE-A274-4D99-830D-D08AE9F91C39Q38650328-0413D971-E5C6-43FB-AD49-46942EB6641BQ40235024-C323B130-3619-4409-86B9-4C8156A9A2ADQ40468912-8C9C5214-1DC3-4D99-B92C-A9D7D709AC00Q40550187-AE3AAC01-B7F6-47ED-95CF-48032F9928B6Q47681393-C10EF958-6863-4829-8348-94568AC77FACQ47756618-4198D22D-F810-45F0-BB82-37325C68439BQ52718642-586C7E9E-1773-44C6-8366-EC9F777E22ECQ53066540-3AFED883-1584-44B6-8530-7A2DBF9C922DQ55074144-701B6DFE-DA95-42F8-AACE-8B6BA20A1DA3Q55139939-76EBF428-59D8-4D84-98C4-2208C3DB986AQ57419693-35FEA4FA-B14C-403A-BA12-0E011C8BA8FCQ58793783-1D037A93-7EC1-419A-9F75-E3F9F9122A80
P2860
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@en
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@nl
type
label
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@en
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@nl
prefLabel
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@en
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@nl
P2093
P2860
P50
P1433
P1476
A prospective study of 67 seru ...... risk of non-Hodgkin lymphoma.
@en
P2093
Anil K Chaturvedi
Jonathan N Hofmann
Ju-Hyun Park
Ligia A Pinto
Ruth M Pfeiffer
Troy J Kemp
P2860
P304
P356
10.1182/BLOOD-2013-01-481077
P407
P577
2013-06-27T00:00:00Z